Document is current
Any future updates will be listed below
-
Authors
Kaluarachchi, D. C. https://orcid.org/0000-0001-8334-6282
Chock, V. Y. https://orcid.org/0000-0002-6942-1423
Do, B. T. https://orcid.org/0000-0002-6012-1168
Rysavy, M. A. https://orcid.org/0000-0002-1209-6607
Sankar, M. N. https://orcid.org/0000-0002-7012-0222
Laughon, M. M. https://orcid.org/0000-0002-4052-3215
Backes, C. H.
Colaizy, T. T.
Bell, E. F. https://orcid.org/0000-0002-5568-0889
McNamara, P. J. https://orcid.org/0000-0001-7648-8872
Hintz, S. R. https://orcid.org/0000-0001-7023-4433
Natarajan, G. https://orcid.org/0000-0003-0464-771X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1 TR6, UL1 TR41, UL1 TR42, UL1 TR77, UL1 TR93, UL1 TR105, UL1 TR442, UL1 TR454, UL1 TR1117)
- License Information
-
More Information
Article History
Received: 27 May 2025
Revised: 6 August 2025
Accepted: 2 September 2025
First Online: 23 September 2025
Competing interests
: Dr. Kaluarachchi serves as a consultant for ONY Biotech Inc. Dr. Backes has following disclosures—Abbott Laboratories: funding of ongoing multicenter trial, in partnership with National Institutes of Health, entitled PIVOTAL (NCT05547165). Abbott Laboratories has no part in the design or execution of PIVOTAL. Dr. McNamara serves as a consultant for Aspect Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
